Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 300 Frank W. Burr Blvd. Suite 21, 65 Challenger Road TEANECK NJ 07666 |
Tel: | N/A |
Website: | https://www.pahc.com |
IR: | See website |
Key People | ||
Jack C. Bendheim Chairman of the Board, President, Chief Executive Officer | Glenn C. David Chief Financial Officer | Jonathan Bendheim Director, President of MACIE Region and General Manager of Israel Operations |
Rob Aukerman President, North America Region | Larry Lee Miller Chief Operating Officer | Daniel M. Bendheim Executive Vice President - Corporate Strategy, Director |
Judith A. Weinstein Senior Vice President, General Counsel, Corporate Secretary | Lisa A. Escudero Senior Vice President - Human Resources | Anthony Andolino Vice President - Finance, Treasurer |
Business Overview |
Phibro Animal Health Corporation is a diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 770 product lines in over 80 countries to approximately 4,000 customers. The Company has three segments. Animal Health segment develops, manufactures and markets about 270 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. Mineral Nutrition segment manufactures and markets approximately 420 formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States. |
Financial Overview |
For the six months ended 31 December 2023, Phibro Animal Health Corp revenues increased 1% to $481.3M. Net loss totaled $6.7M vs. income of $11.1M. Revenues reflect Animal Health segment increase of 5% to $333.6M, Latin America and Canada segment increase of 17% to $123.9M, Asia Pacific segment increase of 2% to $29.2M. Net loss reflects Foreign currency (gains) losses, net increase from $5.1M to $14.2M (expense). |
Employees: | 1,920 as of Jun 30, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $906.12M as of Dec 31, 2023 |
Annual revenue (TTM): | $982.01M as of Dec 31, 2023 |
EBITDA (TTM): | $107.65M as of Dec 31, 2023 |
Net annual income (TTM): | $14.80M as of Dec 31, 2023 |
Free cash flow (TTM): | $17.58M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $382.41M as of Dec 31, 2023 |
Shares outstanding: | 40,503,608 as of Feb 2, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |